PubMed Health⌕ Search

Biomedical subjects

E Schaub

Publications and source records attributed to E Schaub.

11 recordsLinked to original sources

Pain on injection: a double-blind comparison of propofol with lidocaine pretreatment versus propofol formulated with long- and medium-chain triglycerides.

The incidence of pain on injection of propofol has been reported to be 70%. A new propofol formulation with a 10% emulsion of long- and medium-chain triglycerides (LCT/MCT) is associated with less pain on injection. Our goal was to compare the effect of propofol-LCT/MCT on the incidence of pain versus propofol with lidocaine 40 mg IV pretreatment injected as a Bier's block. Two hundred healthy women scheduled for ambulatory gynecological procedures were allocated to 1 of 2 groups in a randomized double-blind fashion. Group LIDO received lidocaine 2% 2 mL injected with a tourniquet 1 min before propofol 1% 2 mg/kg IV; group LCT/MCT received NaCl 0.9% 2 mL with tourniquet 1 min before propofol-LCT/MCT 1% 2 mg/kg IV. Spontaneous verbal expressions of pain, movement of hand, frowning, and moaning during the injection were recorded. The incidence and severity of pain were assessed 30 min and 6 h after surgery. Recall of pain was considered with a visual analog scale (VAS) score >1, and pain was graded as VAS 0-10. More women reported spontaneous verbal expression of pain with propofol-LCT/MCT (47% versus 24%; P = 0.0014; relative risk 1.61 [95% confidence interval, 1.22-2.13]). Among women with a painful injection, there was no difference after surgery regarding the intensity of pain or recall of pain. In contrast to previous reports, we found that propofol-LCT/MCT resulted in a more frequent incidence of pain than propofol 1% with IV lidocaine pretreatment. This may be due to the diversity of pain definitions used in studies or to the lack of premedication in our study.

Adolescent↗

Structure/histotoxicity relationship of parenteral iron preparations.

Commercial iron preparations with different chemical structures and stabilities which are indicated for parenteral application were analyzed. After intravenous application in mice, toxic effects were screened by histological examination of liver, kidney, adrenal, lung and spleen. The various iron complexes were classified into four groups according to their physicochemical properties (molecular mass, kinetic and thermodynamic stability). It was found that the toxic effects can be forecasted by the chemical properties. The results clearly show that not all iron preparations tested can be recommended for intravenous application. After injection, the ideal iron preparation is deposited in the reticulo-endothelial system, and not in the parenchyma of the liver, nor mainly in the periportal area. Furthermore, its renal elimination rate should be below 1% of the dose, and there should be practically no iron detectable in the tubuli. The molecular mass of an optimal product is between 30,000 and 100,000 Daltons, and the preparation does not contain any slowly degradable biopolymers, so that the incidence of allergic side effects is reduced to a minimum. Iron preparations consisting only of weak iron complexes, which liberate iron ions stochastically, should not be used for intravenous application.

Animals↗